MRS Measurement of Glutamate and GABA Metabolism in Brain
ConditionNormal Physiology
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNational Institute of Mental Health (NIMH)
About this trial
This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of \[13\]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA)....
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18-65 years of age
Able to give written informed consent
Healthy based on medical history and physical exam
Enrolled in Protocol 01-M-0254 or Protocol 17-M-0181
Disqualifiers
Any current Axis 1 diagnosis
Clinically significant laboratory abnormalities
Positive HIV test
Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
Trial design
Design model
Single group
Treatments tested in this trial
3T and 7T device
Device3T and 7T device
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: One armOther 1 intervention
Trial outcomes
Primary outcomes
1
The primary outcome is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR)\ ratio, spectral lineshape, linewidth, and resolution.
To obtain more accurate and reliable MRS data from the human brain
Time frame
prospective and ongoingSecondary outcomes
1
The secondary outcome is the performance improvements of the scanner hardware, software and methodology
To obtain more accurate and reliable MRS data from the human brain.
Time frame
prospective and ongoingSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov